使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to the Baxter International's fourth-quarter 2015 earnings conference call.
各位女士、各位先生,早安,歡迎參加百特國際(Baxter International)2015 年第四季財報電話會議。
(Operator Instructions)
(接線員指示)
As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be re-recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得再次錄音或轉播。如有任何異議,請於此時中斷連線。
I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想將電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。
- VP of IR
- VP of IR
Thanks, Stephanie. Good morning and welcome to our fourth quarter 2015 earnings conference call. Joining me today are Joe Almeida, Baxter's new Chairman and Chief Executive Officer, and Jay Saccaro, Baxter's Chief Financial Officer. On the call this morning, we will be discussing Baxter's fourth quarter financial results and outlook for 2016 before taking your questions.
謝謝你,Stephanie。各位早安,歡迎參加我們 2015 年第四季財報電話會議。今天與我一同出席的有百特新任董事長暨執行長 Joe Almeida,以及百特財務長 Jay Saccaro。今天早上的電話會議中,我們將在回答各位提問之前,先討論百特第四季財務結果以及 2016 年展望。
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product developments and regulatory matters, contains forward-looking statements that involve risks and uncertainties and, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.
在此,我先以預先準備的發言開場,提醒各位:本簡報(包括關於我們財務展望、新產品開發與法規事項的評論)包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以了解可能導致實際結果與預期有重大差異之因素的更多細節。
In addition, on today's call non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website. Now I'd like to turn the call over to Joe. Joe?
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比較 GAAP 財務衡量指標的調節表,已包含於我們今早發布並可於官網取得的財報新聞稿中。現在我想把電話交給 Joe。Joe?
- Chairman and CEO
- Chairman and CEO
Thanks, Clare. Good morning and thanks for joining us. Before commenting on our performance in the fourth quarter, I wanted to share a few initial impressions of what I have observed during the past several weeks and why I'm excited about the opportunities that lay ahead.
謝謝你,Clare。各位早安,感謝各位加入我們。在評論我們第四季表現之前,我想先分享過去幾週我所觀察到的一些初步印象,以及為何我對未來的機會感到振奮。
Clearly, we're building on a very strong foundation. Baxter has established one of the most trusted and respected brands in the healthcare industry and over this rich history, we have built a durable portfolio of market-leading products' broad geography reach that spans more than 100 countries.
很明顯地,我們正建立在非常堅實的基礎之上。百特在醫療保健產業建立了最受信賴且備受尊敬的品牌之一;在這段豐富的歷史中,我們打造了耐久的產品組合,擁有市場領先的產品與廣泛的地理覆蓋,遍及超過 100 個國家。
Clearly, we have an outstanding base for expanding margins and accelerating performance; and following last year's spinoff of Baxalta, we can now devote our attention to these strategies and investments that will drive profitable growth across the business and create value as we aspire to deliver top quartile total shareholder returns for our investors.
顯然,我們具備擴大利潤率並加速績效的卓越基礎;而在去年分拆 Baxalta 之後,我們如今可以將注意力投入於這些策略與投資,推動全公司獲利性成長並創造價值,並以為投資人帶來同業前四分位的股東總報酬為目標。
The initial steps are already well underway, which is reflected in Baxter's fourth quarter results. As you saw in this morning's release, we delivered adjusted earnings of $0.43 per diluted share, exceeding our guidance of $0.30 to $0.32 per diluted share. Operating income, up 10.7%, compared favorably to our guidance of 9.5% to 10%. After adjusting for the impact of foreign exchange in the generic market and in the US for cyclophosphamide, we reported sales growth of 4% in the quarter, also ahead of our expectations.
初步步驟已在積極推進中,這也反映在百特第四季的結果上。如各位今早在新聞稿中所見,我們的調整後每股稀釋盈餘為 0.43 美元,優於我們先前提供的每股稀釋盈餘 0.30 至 0.32 美元指引。營業利益成長 10.7%,亦優於我們 9.5% 至 10% 的指引。在就外匯影響、學名藥市場以及美國環磷醯胺(cyclophosphamide)因素進行調整後,我們第四季銷售成長 4%,同樣高於預期。
Key growth drivers in the quarter included a strong performance in our US Fluid Systems franchise, where our nearly launched SIGMA SPECTRUM infusion pump continues to build momentum, as well as increase the demand and favorable pricing for our IV solutions. Performance was augmented by strengthen in our US Peritoneal Dialysis business, which reported the highest quarterly growth of the year.
本季主要成長動能包括我們美國輸液系統(US Fluid Systems)事業群的強勁表現;我們近來推出的 SIGMA SPECTRUM 輸注幫浦持續累積動能,同時 IV 輸液產品的需求增加且定價有利。此外,我們美國腹膜透析(US Peritoneal Dialysis)業務的走強也帶動了表現,該業務創下全年最高的單季成長。
The US PD business has seen very promising early results on the recent launch of our AMIA APD cycler, which features our SHARESOURCE two-way connectivity platform, and we look forward to expanding this launch in 2016. So overall, a positive quarter and a great base to build on for the future.
美國腹膜透析業務在近期推出 AMIA APD 自動腹膜透析機(cycler)後,已看到非常令人鼓舞的早期成果;該產品具備我們 SHARESOURCE 雙向連線平台,我們期待在 2016 年擴大推廣。因此整體而言,這是一個正向的季度,也為未來奠定了良好的基礎。
As for what the future looks like, we're in process of developing a strategic framework that will shape our priorities and direct our approach and investments moving forward. I'm confident this framework will drive sustainable growth for Baxter and create enhanced value for our shareholders.
至於未來展望,我們正在制定一套策略架構,以形塑我們的優先事項,並引導我們後續的作法與投資方向。我有信心,這套架構將推動百特的永續成長,並為股東創造更高的價值。
Simply put, our objective is to further accelerate and increase the impact of our margin improvement plans to support our goal of top quartile shareholder return. To successfully achieve this outcome, we will execute on three distinct strategic [factors], including portfolio optimization, operational excellence, and capital allocation.
簡而言之,我們的目標是進一步加速並放大我們利潤率改善計畫的影響,以支持我們達成同業前四分位股東報酬的目標。為成功達成此一成果,我們將在三個明確的策略[要素]上執行,包括產品組合最佳化、營運卓越,以及資本配置。
In terms of portfolio optimization, we'll take a dispassionate approach to portfolio management, which will include categorize our businesses based on the existing financial profile and future potential, and accordingly, we will reallocate investments based on the ability to drive innovation. In addition, we're intensifying our focus on both R&D velocity and productivity to support our top and bottom line growth initiatives.
在產品組合最佳化方面,我們將以客觀理性的方式進行產品組合管理,其中包括依據現有財務概況與未來潛力對各項業務分類,並相應地依其推動創新的能力重新配置投資。此外,我們也將加強聚焦研發速度與生產力,以支持營收與獲利成長的各項計畫。
The second area of the strategic focus is operational excellence. We are aggressively examining our cost structure in terms of how we do business from manufacturing and operations to commercial and our corporate infrastructure. I'm confident we can take additional costs out of our business without compromise our commitment to quality and safety. Related to this, we also ensure our capital expenditures are optimally allocated to projects that enhance bottom line growth and support long-term value creation.
第二個策略聚焦領域是營運卓越。我們正積極檢視成本結構,涵蓋從製造與營運到商業端以及公司基礎架構的各個面向。我有信心,我們可以在不犧牲對品質與安全承諾的前提下,進一步降低成本。與此相關,我們也將確保資本支出能最佳化配置於可提升獲利成長並支持長期價值創造的專案。
And the final strategic focus area for us is capital allocation, where we are committed to deploying capital in a manner that creates value over both the short- and long-term. We'll be sharing more information about our strategy at our upcoming Investor Day on May 9 in New York City. At that meeting, we will provide more specifics around our objectives, along with our 3- and 5-year aspirational financial targets.
最後一個策略聚焦領域是資本配置;我們承諾以能在短期與長期皆創造價值的方式運用資本。我們將在 5 月 9 日於紐約市舉行的投資人日(Investor Day)分享更多策略資訊。在該會議上,我們將就目標提供更具體的說明,並提出 3 年與 5 年的願景式財務目標。
We know there's a lot of hard work in front of us, but our team is energized and well prepared for the road ahead. And with that, I will pass it to Jay for more details on our fourth quarter performance and outlook for 2016, then we'll have time at the end for questions. Jay?
我們知道前方仍有大量艱鉅工作,但我們的團隊充滿幹勁,也已為前方道路做好充分準備。接下來我將把電話交給 Jay,請他就第四季表現與 2016 年展望提供更多細節,之後我們會在最後留時間回答問題。Jay?
- CFO
- CFO
Thanks, Joe, and good morning, everyone. As Joe mentioned, adjusted earnings in the quarter of $0.43 per diluted share exceeded our previously issued guidance of $0.30 to $0.32 per diluted share. Sales growth in the quarter benefited from strong operational performance in our Fluid Systems, PD and Acute businesses, as well as operating expense savings resulting from our disciplined management of costs and the restructuring initiative we announced last quarter. In addition, other income from foreign exchange related gains and a favorable tax rate both contributed to outperformance in the quarter.
謝謝你,Joe,各位早安。如 Joe 所提到,本季調整後每股稀釋盈餘 0.43 美元,優於我們先前發布的每股稀釋盈餘 0.30 至 0.32 美元指引。本季銷售成長受惠於我們輸液系統、腹膜透析(PD)與急性照護(Acute)業務的強勁營運表現,以及我們嚴謹的成本管理與上季宣布的重整計畫所帶來的營業費用節省。此外,外匯相關收益帶來的其他收入,以及較有利的稅率,也共同促成本季優於預期的表現。
Now, let me briefly walk you through the P&L by line item before turning to the financial outlook for 2016. Starting with sales, worldwide revenues of $2.6 billion increased 2% on a constant currency basis. This performance compares favorably to our Q4 guidance of a 1% sales decline, with better than expected sales growth observed across the portfolio, particularly in our Fluid Systems, Integrated Pharmacy Solutions, and Renal franchises.
現在,在談到 2016 年財務展望之前,我先按損益表(P&L)各項目簡要帶各位看一遍。先從銷售額開始:全球營收 26 億美元,以固定匯率計成長 2%。此一表現優於我們第四季指引所預期的銷售下滑 1%;我們在整體產品組合中觀察到優於預期的銷售成長,尤其是在輸液系統、整合式藥局解決方案(Integrated Pharmacy Solutions)以及腎臟(Renal)事業群。
Including the impact of foreign exchange, sales declined 7% on a reported basis; and excluding the impact of both foreign exchange and US cyclophosphamide, Baxter's sales rose 4% globally. Sales in the US increased 1% on a reported basis; and after adjusting for cyclophosphamide, US sales advanced 7%. International sales on a constant currency basis increased 2% and declined 12% on a reported basis.
若包含外匯影響,按報告基礎計銷售下滑 7%;若排除外匯與美國環磷醯胺(cyclophosphamide)的影響,百特全球銷售成長 4%。美國銷售按報告基礎計成長 1%;若就環磷醯胺進行調整,美國銷售成長 7%。國際銷售以固定匯率計成長 2%,按報告基礎計則下滑 12%。
Turning now to the drivers of business performance in the quarter, please note, I will be speaking to sales growth on a constant currency basis excluding any foreign exchange impact for each of the businesses and franchises to provide a clearer picture of Baxter's underlying operational performance.
現在轉向本季業務表現的驅動因素,請注意,我將以固定匯率基礎來說明各業務與產品線的銷售成長,排除任何外匯影響,以更清楚呈現百特(Baxter)基礎營運表現。
Starting with Hospital Products, global sales totaled $1.6 billion and increased 2%. And after adjusting for US cyclophosphamide, sales for the Hospital Products business increased 5%.
先從醫院產品(Hospital Products)開始,全球銷售額合計16億美元,成長2%。若調整美國環磷醯胺(cyclophosphamide,簡稱cyclo)的影響,醫院產品業務銷售成長5%。
Within the Fluid Systems franchise, sales of $569 million advanced 12%. Performance in the quarter was driven by growth of more than 20% in the Infusion Systems business, supported by the successful launch of our next generation SIGMA SPECTRUM pump and the related access sets pull through. In addition, sales of IV solutions in the quarter benefited from favorable pricing and demand, particularly in the United States.
在輸液系統(Fluid Systems)產品線,銷售額為5.69億美元,成長12%。本季表現主要由輸注系統(Infusion Systems)業務超過20%的成長所帶動,受惠於我們成功推出新一代SIGMA SPECTRUM幫浦,以及相關耗材組(access sets)的連帶拉動。此外,本季靜脈輸液(IV solutions)銷售亦受惠於有利的定價與需求,尤其是在美國。
Sales in the Integrated Pharmacy Solutions franchise totaled $595 million and were comparable to the prior year period. Excluding US cyclo sales, revenues in the category increased 8%, driven by strength across the franchise, which includes our nutritional products, pharmacy injectables, and hospital pharmacy compounding services. Fourth quarter US cyclo sales totaled $65 million, representing a benefit of approximately $10 million versus our previous guidance. For the full year, US cyclo sales totaled approximately $270 million.
整合藥局解決方案(Integrated Pharmacy Solutions)產品線銷售額合計5.95億美元,與去年同期相當。若排除美國cyclo銷售,該類別營收成長8%,動能來自整個產品線的強勁表現,包括我們的營養產品、藥局注射劑,以及醫院藥局調配服務。第四季美國cyclo銷售額為6,500萬美元,較我們先前指引多出約1,000萬美元的貢獻。全年美國cyclo銷售額合計約2.70億美元。
Fourth quarter revenues in Surgical Care, which includes our anesthesia and biosurgery products, totaled $346 million and were comparable to the prior year period. Performance benefited from low single-digit growth of our anesthesia business and core surgical sealant and hemostasis products, which both increased in line with surgical procedure volume growth. This performance was offset by lower sales of select non-core biosurgery products.
第四季外科照護(Surgical Care)營收(包含麻醉與生物外科產品)合計3.46億美元,與去年同期相當。表現受惠於麻醉業務的低個位數成長,以及核心外科封合劑與止血產品的成長;兩者皆與手術量成長一致。上述表現被部分非核心生物外科產品銷售下滑所抵銷。
Finally, sales in the Biopharma Solutions and Other category, which is our former partnering business, totaled $109 million and, as expected, declined 22%. As we've previously highlighted, this decline is driven by a large customer electing to self-manufacture products that were previously contract manufactured by Baxter. As we mentioned last quarter, this category also reflects sales for products Baxter is manufacturing on behalf of Baxalta, which totaled approximately $13 million in the quarter.
最後,生物製藥解決方案及其他(Biopharma Solutions and Other)類別(即我們先前的合作夥伴業務)銷售額合計1.09億美元,如預期下滑22%。如我們先前強調,這一下滑是因一位大型客戶選擇自行生產先前由百特代工的產品所致。如同我們上季提到,該類別亦反映百特代表Baxalta製造產品的銷售額,本季約為1,300萬美元。
Turning to the Renal business, global renal sales totaled $984 million, representing an increase of 1%. Performance in the quarter was driven by high single-digit growth in our US Peritoneal Dialysis business. As Joe mentioned we're very excited about the prospects for this business, which will benefit from the recent launch of our new AMIA PD cycler.
接著看腎臟(Renal)業務,全球腎臟業務銷售額合計9.84億美元,成長1%。本季表現主要由我們美國腹膜透析(Peritoneal Dialysis, PD)業務的高個位數成長所帶動。如Joe所提到,我們對此業務前景非常振奮,近期推出的新AMIA PD自動腹膜透析機(cycler)將帶來助益。
In addition, we experienced low teens growth globally in our Acute business, driven by underlying market growth and an increased adoption of continuous renal replacement therapy as a treatment option for acute kidney injuries. Growth in the Renal business was offset by lower sales in our in-center chronic hemodialysis business, resulting from our previously discussed decision to forgo certain lower margin sales opportunities, along with competitive pressures for dialyzers.
此外,我們的急性(Acute)業務在全球呈現低十位數成長,受惠於基礎市場成長,以及連續性腎臟替代治療(continuous renal replacement therapy, CRRT)作為急性腎損傷治療選項的採用率提升。腎臟業務的成長被院內慢性血液透析(in-center chronic hemodialysis)業務銷售下滑所抵銷,原因包括我們先前討論過的決策:放棄部分較低毛利的銷售機會,以及透析器(dialyzers)的競爭壓力。
Turning to the rest of the P&L, adjusted gross margin for the quarter was 42.6%, slightly ahead of our expectations, driven by favorable product mix in the quarter. Adjusted SG&A totaled $672 million and decreased 17% on a reported basis. On a constant currency basis, adjusted SG&A declined 11%, reflecting the benefit of the initial actions we have taken to rebase our cost structure and reduce discretionary expenses and the impact from transition service income we received from Baxalta during the quarter, which totaled approximately $30 million.
再看損益表其餘項目,本季調整後毛利率為42.6%,略優於我們預期,主要受惠於本季有利的產品組合。調整後銷售、一般及行政費用(SG&A)為6.72億美元,以報表口徑計下降17%。以固定匯率計,調整後SG&A下降11%,反映我們為重設成本結構、降低可控支出所採取的初步行動帶來的效益,以及本季自Baxalta取得的過渡服務收入影響,該收入約為3,000萬美元。
Adjusted R&D spending in the quarter of $158 million increased 2% versus the prior year. On a constant currency basis, adjusted R&D expenditures increased 9%, as we balance increased investments to support our new product pipeline with efforts to optimize our overall R&D spend. Consistent with our portfolio optimization priorities, during the quarter we made the decision to discontinue the development of select programs, and as a result, absorbed approximately $15 million in expenses related to these decisions.
本季調整後研發(R&D)支出為1.58億美元,較去年同期增加2%。以固定匯率計,調整後研發支出增加9%,因我們在支持新產品研發管線的加大投資與優化整體研發支出之間取得平衡。依循我們的產品組合優化優先事項,本季我們決定停止部分專案的開發,因此吸收了約1,500萬美元與這些決策相關的費用。
Adjusted operating margin in the quarter was 10.7%, which compared favorably to our guidance of 9.5% to 10%, driven by the positive gross margin mix and SG&A savings I just referenced. And as Joe mentioned earlier, we'll continue to streamline our operations and control spending to drive ongoing margin expansion. Interest expense was $32 million in the fourth quarter.
本季調整後營業利益率為10.7%,優於我們9.5%至10%的指引,主要受惠於正向的毛利組合與我剛提到的SG&A節省。此外,如Joe先前所述,我們將持續精簡營運並控管支出,以推動持續的利潤率擴張。第四季利息費用為3,200萬美元。
Last week, we executed our first transaction with respect to the retained Baxalta stake. In this transaction, we exchanged approximately 38 million Baxalta shares, or approximately 28% of the total original equity stake, to retire $1.45 billion of indebtedness under one of our bank lines. Over the next several months, we'll look to further deploy the remaining Baxalta equity through a combination of additional debt for equity and equity for equity exchanges, as well as make a contribution of at least $600 million worth of equity to our US-qualified pension plan, subject to final regulatory approval.
上週,我們就保留的Baxalta持股執行了第一筆交易。在此交易中,我們以約3,800萬股Baxalta股票(約占原始股權持股總額的28%)進行交換,用以償還我們其中一條銀行授信項下的14.5億美元債務。在接下來幾個月,我們將透過額外的「以股換債」與「以股換股」交換組合,進一步運用剩餘的Baxalta股權;同時亦將在取得最終監管核准的前提下,向我們符合美國資格的退休金計畫(US-qualified pension plan)投入至少價值6億美元的股權。
Our goal is to exit our retained equity position prior to any shareholder vote for the Baxalta-Shire transaction to minimize the risk of any potential negative tax implications; and we have an agreement in place with Shire and Baxalta to assist with the orderly disposition of the stake. For 2016, we expect these retained stake-related actions to benefit our earnings by approximately $0.15 per diluted share.
我們的目標是在Baxalta與Shire交易進行任何股東表決之前,退出我們保留的股權部位,以降低任何潛在不利稅務影響的風險;且我們已與Shire及Baxalta達成協議,以協助有序處分該持股。就2016年而言,我們預期這些與保留持股相關的行動將使每股稀釋盈餘(EPS)增加約0.15美元。
In terms of key balance sheet items, after giving effect to the extinguishment of the bank line, our current gross outstanding debt balance is approximately $5 billion and cash on hand at the end of 2015 totaled approximately $2.2 billion. Other income totaled $36 million and included a foreign exchange gain from hedges on balance sheet positions of approximately $20 million and dividend income of approximately $10 million associated with our Baxalta equity stake.
就資產負債表的關鍵項目而言,在反映該銀行授信債務清償後,我們目前的未償還總負債餘額約為50億美元,而2015年底的現金及約當現金約為22億美元。其他收入合計3,600萬美元,其中包括就資產負債表部位所做避險產生的外匯收益約2,000萬美元,以及與我們持有的Baxalta股權相關的股利收入約1,000萬美元。
The adjusted tax rate was 16.6% for the quarter. This compared favorably to our guidance and contributed approximately $0.02 to our earnings per share in the quarter. The lower tax rate was driven by the extension of the R&D tax credit, a slight shift in our sales mix, and certain other adjustments. And as previously mentioned, adjusted earnings of $0.43 per diluted share exceeded our guidance of $0.30 to $0.32 per share.
本季調整後有效稅率為16.6%。此結果優於我們的指引,並使本季每股盈餘增加約0.02美元。較低的稅率主要由研發稅額抵減(R&D tax credit)延長、銷售組合的些微變化,以及其他若干調整所驅動。此外,如先前所述,調整後每股稀釋盈餘0.43美元,高於我們每股0.30至0.32美元的指引。
Let me conclude my comments this morning by providing an update on our outlook for 2016. Starting with sales on a constant currency basis, we expect 2016 full-year sales for Baxter to increase 2% to 3%; and after adjusting for the US cyclo impact, we expect underlying growth of 3% to 4%. On a reported basis, including the impact of foreign exchange, we expect sales to decline approximately 1%. This is driven by growth in the Hospital Products business of 2% to 3%, or 4% to 5% excluding US cyclo.
最後,讓我在今天上午的發言以更新我們對2016年的展望作結。先從固定匯率口徑的銷售來看,我們預期百特2016年全年銷售將成長2%至3%;若調整美國cyclo影響,我們預期基礎成長為3%至4%。以報表口徑(包含外匯影響)計,我們預期銷售約下滑1%。此展望由醫院產品業務2%至3%的成長所帶動;若排除美國cyclo,則為4%至5%。
Within the Hospital Products franchises, we expect sales growth of 6% to 8% for Fluid Systems, driven by strength in the US business partially offset by the international business, where we continue our efforts to optimize our geographic footprint for this franchise. For the Integrated Pharmacy solutions franchise, we expect sales to decline mid single-digits, including the impact of US cyclo.
在醫院產品各產品線中,我們預期輸液系統(Fluid Systems)銷售成長6%至8%,主要由美國業務的強勁表現帶動,但部分將被國際業務所抵銷;在國際市場方面,我們將持續推動該產品線的地理布局最佳化。就整合藥局解決方案(Integrated Pharmacy Solutions)產品線而言,我們預期銷售將下滑中個位數百分比,並包含美國cyclo的影響。
For full-year 2016, we anticipate at least two additional competitive entrants, specifically one to enter mid-year and the second to enter towards the latter part of 2016. As a result we expect US cyclophosphamide sales to total approximately $180 million, representing a $90 million year-over-year decline. Sales for the category, after adjusting for cyclophosphamide, are expected to be comparable to prior years.
就2016全年而言,我們預期至少會有另外兩家競爭對手進入市場,具體而言,一家將於年中進入,第二家將於2016年後段進入。因此,我們預期美國環磷醯胺(cyclophosphamide)銷售額合計約為1.8億美元,較去年同期下降9,000萬美元。在扣除環磷醯胺影響後,該類別的銷售預期將與前幾年大致相當。
I would also remind you that in 2015, we recognized approximately $40 million in government sales for PROTOPAM. Given the purchasing pattern associated with this product, we do not anticipate any sales in 2016 in IPS.
我也想提醒各位,2015年我們確認了約4,000萬美元的PROTOPAM政府銷售。鑑於此產品的採購模式,我們預期2016年在IPS不會有任何銷售。
Within the Surgical Care franchise, we anticipate sales to grow 2% to 3%. And finally, for the Hospital Products business, we expect the Other category, which includes our biopharma solutions franchise, to increase low double-digits as we anniversary the impact of our customer transitioning their manufacturing in house. This also reflects an incremental year-over-year benefit of approximately $25 million associated with contract manufacturing revenues from Baxalta.
在外科護理(Surgical Care)事業群方面,我們預期銷售將成長2%至3%。最後,就醫院產品(Hospital Products)業務而言,我們預期「其他」類別(包含我們的生物製藥解決方案事業群)將在我們度過客戶將其製造轉回自建產能的影響周年後,呈現低雙位數成長。這也反映了與Baxalta合約製造收入相關、約2,500萬美元的額外年增效益。
For the Renal business, we expect full-year sales to increase approximately 3%, driven by continued growth in our PD and Acute businesses and a stabilization in our in-center HD business.
在腎臟(Renal)業務方面,我們預期全年銷售將增加約3%,主要由腹膜透析(PD)與急性(Acute)業務的持續成長,以及院內血液透析(in-center HD)業務的趨於穩定所帶動。
Moving down the P&L, we expect an operating margin of approximately 11%, which compares favorably to the guidance we provided at our 2015 May investor conference of approximately 10%. We expect interest expense to total approximately $90 million. This reflects the recent extinguishment of our bank line, along with additional debt repayment based on further utilization of the retained stake.
往下看損益表(P&L),我們預期營業利益率約為11%,相較於我們在2015年5月投資人會議所提供約10%的指引更為有利。我們預期利息費用合計約為9,000萬美元。這反映了我們近期清償銀行授信額度,以及基於進一步運用保留持股(retained stake)所進行的額外債務償還。
For 2016, we expect modest other income of approximately $10 million. This represents a year-over-year decline of approximately $150 million. In 2015, we benefited from certain balance sheet hedge gains and select equity gains related to our Baxter Ventures portfolio, neither of which is planned to repeat in 2016.
就2016年而言,我們預期其他收益約為1,000萬美元,屬於溫和水準。這代表較去年同期約下降1.5億美元。2015年我們受惠於部分資產負債表避險收益,以及與我們Baxter Ventures投資組合相關的特定股權收益;這兩者在2016年皆不預期重現。
For the year, we expect an average adjusted tax rate of 19.5% to 20%. This represents an increase from 2015, driven primarily by the change in earnings mix.
全年而言,我們預期平均調整後有效稅率為19.5%至20%。相較2015年有所上升,主要由獲利組合(earnings mix)的變化所驅動。
For 2016, we anticipate an average share count of approximately 540 million shares. This reduction is driven by equity for equity exchanges that we anticipate to execute as part of our retained stake strategy later in the second quarter.
就2016年而言,我們預期平均流通股數約為5.4億股。此一減少主要來自我們預期在第二季後段、作為保留持股策略一部分所執行的以股換股(equity-for-equity)交換。
Please note that our interest expense and share count guidance reflects a preliminary base case retained stake execution plan and is subject to change as we reassess the optimal size and mix of our remaining transactions, as market and other conditions evolve. We anticipate providing updates to our guidance and additional detail around the actual impacts of our retained stake transactions, as appropriate, as we move forward.
請注意,我們的利息費用與股數指引反映的是一個初步的保留持股執行計畫基準情境(base case),並可能隨著我們在市場及其他條件演變下,重新評估剩餘交易的最佳規模與組合而有所變動。隨著後續推進,我們預期將在適當時點更新指引,並就保留持股交易的實際影響提供更多細節。
Based on these factors, we expect adjusted earnings, excluding special items, of $1.46 to $1.54 per diluted share for 2016. Finally, for the year, we expect operating cash flow of approximately $1.4 billion and CapEx of approximately $900 million, resulting in free cash flow for 2016 of approximately $500 million. This is also favorable to the guidance we provided in May.
基於上述因素,我們預期2016年調整後每股盈餘(不含特殊項目)為稀釋後每股1.46至1.54美元。最後,全年我們預期營運現金流約為14億美元,資本支出(CapEx)約為9億美元,因此2016年自由現金流約為5億美元。這也優於我們在5月所提供的指引。
Specific to the first quarter of 2016, we expect sales growth, excluding the impact of foreign currency, to increase 3% to 4%. At current foreign exchange rates, we expect reported sales to decline approximately 2%. And we expect adjusted earnings, excluding special items, of $0.28 to $0.30 per diluted share.
就2016年第一季而言,我們預期在排除外幣影響後,銷售成長將增加3%至4%。以目前匯率計算,我們預期報告銷售額將下降約2%。此外,我們預期調整後每股盈餘(不含特殊項目)為稀釋後每股0.28至0.30美元。
With that, we can now open up the call for Q&A.
接下來,我們現在可以開放問答(Q&A)。
Operator
Operator
Thank you.
謝謝。
(Operator Instructions)
(接線員指示)
I would like to remind participants that this call is being recorded, and a digital replay will be available on the Baxter International's website for 30 days, at www.Baxter.com.
我想提醒與會者,本次電話會議將被錄音,並且在Baxter International網站上將提供為期30天的數位重播,網址為www.Baxter.com。
Our first question comes from David Roman with Goldman Sachs. Your line is open.
我們的第一個問題來自高盛(Goldman Sachs)的David Roman。您的線路已開通。
- Analyst
- Analyst
Thank you. Good morning, everybody.
謝謝。各位早安。
- Chairman and CEO
- Chairman and CEO
Good morning, David.
早安,David。
- Analyst
- Analyst
Hello, Joe. Good to hear your voice again here. I wanted to start with one strategic question, then one follow-up on the financial side. And Joe, I imagine you'll get into this in more detail come May, but maybe you could just start from a top down perspective and where are you ultimately hoping to take Baxter. As I think about the profile of the business today, relatively low single-digit top line growth, room for margin expansion, how do you want the business to be perceived and where do you ultimately want to take the story over time?
你好,Joe。很高興再次聽到你的聲音。我想先問一個策略性問題,接著再就財務面追問一題。Joe,我想你在5月會更詳細說明,但也許你可以先從自上而下的角度談談,你最終希望把Baxter帶往哪裡。以我對目前業務輪廓的理解,營收端是相對低個位數成長,且仍有擴大利潤率的空間;你希望市場如何看待這門生意?以及隨著時間推進,你最終希望把這個故事帶到什麼位置?
- Chairman and CEO
- Chairman and CEO
David, I don't want to preempt our meeting in May, but I will give you a few things that we're considering very seriously. First of all is taking from the top, we need to alter the weighted average market growth rate of our businesses. By doing that, we will look at some organic programs that can help us get into some adjacent markets, and also some acquisitions.
David,我不想搶先於我們5月的會議,但我可以先分享幾點我們正在非常認真考量的事項。首先,從最上層來看,我們需要改變各項業務的加權平均市場成長率。為此,我們會檢視一些有機成長計畫,協助我們進入相鄰市場,同時也會考慮一些併購。
When also we look at execution, we need to continue to improve our execution on a global basis and make sure that we are in the right businesses around the globe. Being global is not to be all over the place, so we need to make sure that we're focusing in countries and geographies for businesses that make sense. So all this work is in process, as we speak.
此外,談到執行面,我們需要持續在全球範圍內提升執行力,並確保我們在全球各地所處的業務是正確的。全球化並不代表到處撒網,因此我們必須確保聚焦於在各國家與地理區域中、對我們業務而言合理且有意義的市場。所以,這些工作此刻都正在進行中。
When I look at on the cost base and expense, we want to take the Company to a rebase exercise, cost rebase, and find out what is the appropriate level of support that we need to maintain our Company and provide for continuous improvement and operational excellence programs that will deliver better results that we have spoken about in terms of operating income back in May last year.
就成本基礎與費用而言,我們希望推動公司進行一次重新基準化(rebase)作業,也就是成本重置(cost rebase),以釐清為了維持公司運作所需的適當支援水準,並支撐持續改善與營運卓越計畫,從而帶來更好的成果——也就是我們去年5月在談到營業利益時所提及的那些成果。
So we are working very diligently right now in creating this strategic framework. We're working on our portfolio initiatives. But we understand, some of these initiatives on the top line take a little longer. And I have no issues augmenting that with some acquisitions and I have no problems accelerating our cost reduction rebase and the costs of the Company to be able to create momentum until we can get the innovation machine reignited again.
因此,我們目前正非常努力地建立這個策略框架。我們也在推進投資組合相關的各項計畫。但我們也理解,其中一些營收端的計畫需要更長時間才能見效。我完全不排斥透過一些併購來補強,同時我也願意加速推動成本削減的重新基準化,以及公司成本結構的調整,以便在我們重新點燃創新引擎之前,先建立動能。
- Analyst
- Analyst
That's very helpful. Thank you. And then just on the financial side, Jay, maybe you can help us talk through the difference between the 10% operating margin guidance that you provided at last May's analysts meeting and the 11% that you're presenting today for 2016. What are some of the factors that influence the 100 basis point better performance?
這非常有幫助。謝謝。接著就財務面,Jay,也許你可以協助我們梳理一下:你們在去年5月分析師會議提供的2016年10%營業利益率指引,與今天提出的2016年11%之間的差異。有哪些因素促成了這多出100個基點的更佳表現?
- Chairman and CEO
- Chairman and CEO
Great. So there are a number of different variables that have impacted our performance since we sat together in May. I'll highlight maybe the four most significant. As David pointed out, we guided to an operating margin of 10% for 2016. Obviously, we're very pleased to report our expectations now are an 11% operating income margin.
好的。自從我們在5月坐下來討論以來,有許多不同變數影響了我們的表現。我先強調其中最重要的四項。如David所指出,我們當時對2016年的營業利益率指引為10%。顯然,我們很高興現在可以報告,我們目前的預期是11%的營業利益率。
One of the key drivers relates to foreign exchange. The foreign exchange environment since May has moved very significantly. And we can talk later about EPS impacts. But from an operating margin impact, relative to our May expectations, we're down about 1.4% in terms of margin impact due to foreign exchange. As you recall, in the second half of the year, a lot of the emerging markets currencies moved, while the developing market currencies stabilized. And for us, because we don't hedge emerging market currencies, it did have a 1.4% impact on our overall margin.
其中一個關鍵驅動因素與外匯有關。自5月以來的外匯環境已出現非常顯著的變化。我們稍後也可以談談對EPS的影響。但就營業利益率的影響而言,相較於我們5月的預期,由於外匯因素,我們的利益率影響約下滑1.4%。如各位所記得,在今年下半年,許多新興市場貨幣出現波動,而已開發市場貨幣則趨於穩定。而對我們而言,因為我們不對新興市場貨幣進行避險,這確實對我們整體利益率造成了1.4%的影響。
We did have higher than expected cyclo in 2016. So as I pointed out in my prepared remarks, we'll achieve about $180 million of cyclo sales in 2016. That's roughly 1 percentage point higher than we expected.
我們在2016年的cyclo表現確實高於預期。因此如我在事先準備的發言中指出,我們在2016年將達成約1.8億美元的cyclo銷售額。這大約比我們原先預期高出1個百分點。
We also have positive pension. There are a number of impacts that we have with respect to our pension, some of which we had anticipated, in part related to the contribution of the retained stake, but some of which we did not anticipate. And that's about 60 basis points of improvement as we move to 2016.
我們的退休金也有正面貢獻。就退休金而言,我們受到多項因素影響,其中有些是我們原先預期到的,部分與保留持股的貢獻相關,但也有一些是我們未曾預期的。而當我們進入2016年時,這帶來約60個基點的改善。
But I will tell you, the area that's most important as we look at the stability of the operations, from my perspective, relates to the operational performance and OpEx savings, which contribute about 1 point of margin improvement relative to our May investor conference expectations.
但我要告訴各位,從我個人角度來看,當我們檢視營運穩定性時,最重要的領域與營運表現及營業費用(OpEx)節省有關;相較於我們5月投資人會議的預期,這些因素合計貢獻約1個百分點的利益率改善。
So those are the four factors, with cyclo and pension essentially offsetting FX and then the over achievement, really, in my view, coming from operational strength.
所以這就是四個因素:cyclo與退休金基本上抵消了外匯的影響,而超出預期的部分,在我看來,主要來自營運面的強勁表現。
- Analyst
- Analyst
Thanks for all the detail.
感謝提供這麼多細節。
Operator
Operator
Our next question comes from David Lewis of Morgan Stanley. Your line is open.
我們的下一個問題來自摩根士丹利(Morgan Stanley)的David Lewis。您的線路已開通。
- Analyst
- Analyst
Good morning.
早安。
- Chairman and CEO
- Chairman and CEO
Good morning, David.
早安,David。
- Analyst
- Analyst
Good morning, Joe. Just a couple questions here. I'll start with strategic for Joe and then a follow-up maybe for Jay. Joe, I know we're not going to get a lot of commentary before May, but just very broadly, I know you've only been there a short period of time, a couple questions for you. The first is, how do you see the balance of pursuing large M&A in the near term versus delivering the organic margin plan? And if you think specifically about your Hospital business and the four segments there, do you have a sense of which segments are likely to see further investment versus which ones are likely to be optimized for return or cash? And then a quick follow-up for Jay.
早安,Joe。我這裡有幾個問題。我先問Joe一個策略面的問題,然後可能再追問Jay一個。Joe,我知道在5月之前我們不會得到太多評論,但就非常概括地說,你到任時間不長,我有幾個問題想請教。第一,你如何看待短期內追求大型併購(M&A)與推動有機的利益率計畫之間的平衡?另外,如果特別看你的醫院(Hospital)業務及其四個事業部門,你是否已大致判斷哪些部門可能會進一步加大投資、哪些部門可能會以提升報酬或現金回收為優先來進行最佳化?然後我再快速追問Jay一個問題。
- CFO
- CFO
Yes, David, we almost are completing that analysis. We put our portfolio through about five different filters, and we actually have a pretty good idea of the things that we will invest for top line growth versus ROIC, ones that are strategic bets and ones that we're going to manage more for cash. I would say to you, I'm going to give a few examples.
是的,David,我們幾乎已完成那項分析。我們用大約五種不同的篩選標準來檢視我們的投資組合,實際上我們已相當清楚哪些項目會為了營收成長而投資、哪些會以投資資本報酬率(ROIC)為主,哪些是策略性押注,以及哪些我們會更偏向以現金管理。我可以給你幾個例子。
We have a very good IPS business. The Integrated Pharmacy Solutions is a very good business and is something that we probably can double down. As an example, we will be making organic investments, possibly inorganic investments.
我們有一個非常好的IPS業務。整合藥事解決方案(Integrated Pharmacy Solutions)是一項非常好的業務,我們可能會加碼投入。例如,我們會進行有機投資,也可能進行非有機投資。
I just want to circle back to your comment about large sized M&A. When we go down this path and we look at our inorganic opportunities, size is not what matters, but the ability, the ability to change the weighted average market growth rate of our businesses is key to us. And those acquisitions will be singles and doubles. They will not be big things in one shot. We're going to make right decisions with our shareholders' money. And we need to balance that well, but we need to make sure also that we can successfully integrate and generate a step change in how we grow that business that we acquired.
我想回到你提到的大型併購這點。當我們走這條路、評估非有機機會時,規模並不是重點;對我們而言,關鍵在於是否有能力改變我們各項業務的加權平均市場成長率。而這些收購會是「一壘安打、二壘安打」式的交易。不會是一口氣做很大的案子。我們會用股東的資金做出正確決策。我們需要把這個平衡拿捏好,同時也要確保我們能成功整合,並在所收購的業務成長方式上帶來階躍式的提升。
So we'll be focusing great deal of our attention in the value the business brings to us is strategic. But IPS is a good place to start.
因此我們會把大量注意力放在:該業務為我們帶來的價值是否具策略性。但IPS是一個很好的起點。
- Analyst
- Analyst
Okay. It's very helpful. And then Jay, just on Fluid Systems, with the driver obviously in the quarter and it does seem to be the principal driver for next year's acceleration, can you give us a component right now, what principally is driving the success? I know it's capital and consumable. But can you give us a sense of how large of a role capital sales are playing in 2016, and any sense of backlog in terms of sustainability of those capital sales over the next couple of years? Thank you.
好的。這非常有幫助。接著問Jay,關於流體系統(Fluid Systems),本季的驅動因素很明顯,而且看起來也是明年加速成長的主要驅動力;你能否拆解一下目前主要成功動能來自哪裡?我知道有資本設備與耗材。但你能否讓我們了解,2016年資本設備銷售大概扮演多大的角色?以及就未來幾年資本設備銷售的可持續性而言,是否能分享一些訂單積壓(backlog)的情況?謝謝。
- CFO
- CFO
Yes, sure. I mean, look, we were -- Fluid Systems really has two primary drivers of growth in the fourth quarter. And then also as we move to next year, we'll see similar levels of performance based on those two drivers.
好的,當然。你看,流體系統在第四季的成長主要有兩個驅動因素。而且當我們進入明年時,基於這兩個驅動因素,我們也會看到類似水準的表現。
And the first one, I would say, is the Infusion Systems business. In particular, in the US, we had well north of 20% growth in our Infusion Systems business. And breaking that down, there's two components of that. One is the sale of the SPECTRUM pump, which has recently relaunched. And that clearly is capital related. But as I think about the long-term sustainability of the business, really we were very pleased with the sets associated with that. And so we had very strong performance in set sales as well, well into double digits. So those were the two drivers on the Infusion Systems side.
第一個我會說是輸注系統(Infusion Systems)業務。特別是在美國,我們的輸注系統業務成長率遠高於20%。拆開來看,有兩個組成部分。其一是SPECTRUM幫浦的銷售,該產品近期重新上市。這顯然與資本設備相關。但就業務的長期可持續性而言,我們對與之配套的輸注管路組(sets)表現非常滿意。因此我們在管路組銷售上也有非常強勁的表現,達到兩位數的高成長。這就是輸注系統端的兩個驅動因素。
From an IV Therapy standpoint, we've commented previously about the conditions, the marketplace conditions, some of the actions that we've taken, and also continued demand for this important product. So we did report very solid growth in the IV Therapy business, as well, well into double digits.
就靜脈注射治療(IV Therapy)而言,我們先前已評論過相關情況、市場環境、我們採取的一些行動,以及市場對這項重要產品的持續需求。因此我們在IV Therapy業務也回報了非常穩健的成長,同樣達到兩位數的高成長。
And so in combination, these items contributed to, in the US -- and my growth rates are in relation to the US -- the Fluid Systems growth that we reported of 27%. So clearly, this was a bright spot for us. We do expect this to continue, but of course not at the Q4 rates. So we'll see some moderation as we move to the 2016 plan.
因此綜合來看,這些項目促成了我們在美國——而我提到的成長率都是相對於美國——所回報的流體系統27%的成長。很明顯,這對我們而言是一個亮點。我們確實預期這樣的動能會延續,但當然不會維持在第四季那樣的速度。因此當我們進入2016年計畫時,成長會有所趨緩。
So overall, very pleased with it. Some of it is related to capital spending, but as you know, most hospitals have lacked, for many years, an attractive alternative from a pump standpoint, for a variety of different reasons. So we do believe there is some level of pent-up demand. We have a fairly good line of sight for the sales plan for 2016. So this is an area that I think is really one of the growth drivers for Baxter in 2016 and beyond.
整體而言,我們對此非常滿意。其中一部分與資本支出有關,但如你所知,多年來多數醫院在幫浦方面一直缺乏具吸引力的替代方案,原因有很多。因此我們確實相信存在一定程度的遞延需求(pent-up demand)。我們對2016年的銷售計畫有相當清晰的能見度。所以我認為這會是Baxter在2016年及之後的重要成長驅動因素之一。
- Analyst
- Analyst
Great. Thank you very much.
很好。非常感謝。
Operator
Operator
Our next question comes from Mike Weinstein with JPMorgan.
我們的下一個問題來自摩根大通(JPMorgan)的Mike Weinstein。
- Analyst
- Analyst
Thank you and good morning, everybody. Jay, just want to circle back to a couple of the line items in the guidance. The share count guidance seems to imply that you're going to use $1 billion of the retained remaining Baxalta stake in the stock for stock exchanges. Is that about right, in terms of is that about what you're applying in your assumptions for 2016, and if so, why is that the right mix in terms of what remains?
謝謝,大家早安。Jay,我想回到財測指引中的幾個科目。股數指引似乎意味著你們將使用10億美元的剩餘保留Baxalta持股,來進行以股換股的交換。就你們對2016年的假設而言,這樣理解大致正確嗎?如果是,為什麼在剩餘部位的運用上,這會是合適的組合?
- CFO
- CFO
Yes. Mike, maybe I'll take a step back and address the retained stake overall to address your question in totality. From the retained stake standpoint, there are two things that are very clear to us today. First, as you know, we're in the process of finalizing the bank line transaction, which is going to reduce our gross debt by $1.45 billion. That will be completed imminently. The second item is in this quarter, we expect to contribute more than $600 million in equity to our pension plan. That, of course, is subject to Department of Labor approval. So those things are, in my view, very definitive.
是的。Mike,也許我先退一步,從整體保留持股的角度來回應你的問題。就保留持股而言,今天有兩件事對我們來說非常明確。第一,如你所知,我們正在完成銀行授信交易的最後定案,這將使我們的總負債減少14.5億美元。這將在近期內完成。第二,本季我們預期將向我們的退休金計畫投入超過6億美元的股權。當然,這仍需勞工部核准。因此,在我看來,這些事項都非常明確。
As we move on to the remaining transactions, our preliminary plan is to pursue two additional transactions. One is an equity for debt exchange, and the second is an equity for equity split off. We currently expect to pursue the debt exchange early in Q2 and the equity exchange closer to mid-year.
至於其餘交易,我們的初步規劃是推進另外兩項交易。一項是以股換債(equity for debt exchange),第二項是以股換股的分拆(equity for equity split off)。目前我們預期在第二季初進行換債交易,而以股換股交易則更接近年中。
There's going to be a number of factors that lead us to finally size these transactions. But you're right, from a place holder standpoint, our current view is that we'll use, at Baxalta's current price, a little more than $2 billion to retire debt and a little less than $1 billion to retire equity. But as I've said before, these transactions are subject to market conditions, optimal pricing; and our objective is to maximize long-term value and optimize economics with respect to these transactions.
最終決定這些交易規模會受到多項因素影響。不過你說得對,作為暫定基準,我們目前的看法是,以Baxalta目前的股價計算,我們將動用略高於20億美元來償還債務,並動用略低於10億美元來回購/註銷股權。但如我先前所說,這些交易取決於市場狀況與最佳定價;我們的目標是最大化長期價值,並就這些交易優化經濟效益。
So as far as definitive plans, I can tell you these are our very preliminary plans, but by no means definitive. We're evaluating what the optimal mix is, so there may be changes to these transactions as we move forward, based on the receptivity of the market and a number of other factors. As we finalize plans and execute transactions, clearly, we'll update guidance. But we have enough information today to share with you these preliminary estimates, which provide some balance around the guidance range that we're giving.
因此,就確定性計畫而言,我可以告訴你這些只是非常初步的規劃,絕非定案。我們正在評估最佳組合,所以隨著推進,基於市場接受度及其他多項因素,這些交易可能會有所調整。當我們敲定計畫並執行交易時,顯然也會更新財測指引。但我們目前已有足夠資訊與各位分享這些初步估算,讓我們所提供的指引區間更具平衡性。
In combination, we expect about a $0.15 benefit this year. There would be some increase to next year, in part, because the equity for equities transaction would occur very close to mid-year in this plan assumption, and also the equity for debt exchange, we'd have at least a quarter more of benefit rolling into 2017.
合計而言,我們預期今年約有0.15美元的正面貢獻。明年會再增加一些,部分原因是依此假設,以股換股交易會非常接近年中發生;另外,以股換債交易在2017年也至少會多滾入一個季度的效益。
- Analyst
- Analyst
That's a great overview, Jay. Thanks very much. And Joe, let's just talk strategy for a minute. So you touched on a number of the themes that you talked about in San Francisco, including portfolio optimization and improving R&D productivity, improving the overall growth mix of the business, and being in the top quartile of shareholder returns. The big part of that is putting this Baxalta stake in, ultimately, your balance sheet to work to create value. You talked about doing more likely a series of smaller deals to achieve those objectives. As you think about that, is the number one priority to accelerate the overall mix of growth in the Company's end markets, or should we look at it as more ROIC driven or margin driven? Maybe just help us think about if you're looking -- if you have targets and if you're looking to do something particular for the Company, is it accelerating the top line or how do we think about that mix?
Jay,這個總覽很棒。非常感謝。Joe,我們來談一下策略。你提到了你在舊金山談過的幾個主題,包括投資組合最佳化、提升研發生產力、改善公司整體成長組合,以及讓股東報酬進入同業前四分位。其中很大一部分,是最終把這筆Baxalta持股放到資產負債表上加以運用以創造價值。你提到更可能透過一系列較小的交易來達成這些目標。在你思考這件事時,首要優先事項是加速公司終端市場的整體成長組合,還是應該更以投資資本報酬率(ROIC)或利潤率為驅動?也請幫我們理解一下:如果你有目標、想為公司做一些特定的事,是加速營收成長,還是我們該如何看待這個組合?
- Chairman and CEO
- Chairman and CEO
Well, we're going to, Mike, take a look at -- we have three to five years horizons. So what can we do to change the trajectory of the Company's top line growth and bottom line? What comes first? So we need to -- no, we already have embarked on this very extensive operational excellence program to cut costs. We're going to double down on that and become a little bit more aggressive. That will create some momentum as we continue to look for the opportunities at the top line.
Mike,我們會以三到五年的視角來看。也就是,我們能做什麼來改變公司營收成長與獲利的軌跡?什麼先做?因此我們需要——不,其實我們已經啟動一個非常廣泛的營運卓越計畫來削減成本。我們會加倍投入,並變得更積極一些。這將在我們持續尋找營收端機會的同時,創造一些動能。
When you talk about the capital allocation at top line, we have about four, five businesses that we probably get a significant amount of investment from the Company on the organic arena. I'm going to talk more about that in May. I don't want to preempt that now. But also, we're going to invest inorganically in opportunities for those businesses.
談到資本配置與營收端,我們大概有四、五個事業會在有機成長方面獲得公司相當程度的投資。我會在五月再多談。我不想現在搶先透露。但同時,我們也會以非有機方式投資這些事業的機會。
When we talk about how to hit it well, we want to change -- we want to buy business that they're growing faster than our current base business. That is a pretty obvious thing. The second thing is if we can combine that with good synergistic deal, we'll do it, as well.
談到如何把握得當,我們希望收購的業務其成長速度要快於我們目前的基礎業務。這是很顯而易見的。第二,如果我們還能把它與良好的協同效益交易結合起來,我們也會這麼做。
And why do I put a bracket around very large deals? Because very large deals are very difficult to find. We can keep looking for a deal like that -- it will take a couple of years -- versus just creating a really good strategy by looking at adjacencies and [peppering] good businesses with acquisitions that make sense.
那為什麼我會對非常大型的交易加上括號?因為非常大型的交易非常難找。我們可以一直尋找那樣的交易——可能要花上好幾年——相較之下,不如透過檢視相鄰領域(adjacencies),並用合理的併購去「點綴」優質業務,來建立一個真正好的策略。
I don't discard size, being large. But it's much more difficult to encounter that than something else that will create value almost instantly and you can execute a little faster. So I'm looking at this whole thing as a journey where we make sure that our cost is in place, while we augment our internal innovation and supplement internal innovation with some really well thought out acquisitions.
我不會排除規模、做大。但相較於其他能幾乎立刻創造價值、且執行速度更快的選項,遇到那種機會要困難得多。因此我把整件事視為一段旅程:確保成本結構到位,同時強化內部創新,並以一些深思熟慮的收購來補充內部創新。
- Analyst
- Analyst
Perfect. That's helpful, Joe. Thanks. I'll let somebody jump in.
很好。這很有幫助,Joe。謝謝。我讓其他人接著問。
- Chairman and CEO
- Chairman and CEO
Thank you, Mike.
謝謝你,Mike。
Operator
Operator
Our next question comes from Bob Hopkins with Bank of America.
下一個問題來自美國銀行(Bank of America)的Bob Hopkins。
- Analyst
- Analyst
Thank you and good morning.
謝謝,早安。
- Chairman and CEO
- Chairman and CEO
Good morning, Bob.
早安,Bob。
- Analyst
- Analyst
Good morning, Joe. Great to hear your voice. A couple quick questions. First of all, to start out with, with Jay on the operating margin guidance for 2016, you're exiting the year at just below 11% and you're guiding for 2016 at 11%, and it sounds like cyclo, pension, FX are kind of a wash, so can you give us a sense as to what kind of underlying operating margin improvement you're assuming for 2016 relative to where you're exiting the year?
早安,Joe。很高興聽到你的聲音。有幾個簡短問題。首先,關於2016年的營業利益率指引:你們在年底的退出水準略低於11%,而你們對2016年的指引是11%;聽起來cyclo、退休金、匯率(FX)大致互相抵銷。那你能否讓我們了解一下,相較於今年年底的退出水準,你們對2016年所假設的基礎營業利益率改善幅度大概是多少?
- CFO
- CFO
Yes. There is an important point to make, which is -- and you know this about our business, Bob -- we have seasonality, which typically, the second half of the year is stronger than the first half. And the fourth quarter is typically one of the strongest margin quarters that we have, in large part because of incremental sales performance that naturally occurs.
是的。有一個重要重點要說明——而且你也了解我們的業務特性,Bob——我們有季節性,通常下半年會比上半年更強。而第四季通常是我們毛利/利潤率最強的季度之一,很大程度是因為自然發生的增量銷售表現。
And so as we think about margin performance next year versus this year, I do think it's important to look at the entire year holistically. And if you think about the full year for 2015, we're at about approximately a 9% margin, going to the 11% that we've guided to. So it is a fairly substantial step change improvement in margin.
因此,當我們思考明年的利潤率表現相較於今年時,我確實認為從全年整體角度來看很重要。如果你看2015全年,我們大約是9%的利潤率,提升到我們所指引的11%。所以這是相當顯著的階躍式改善。
The other point I will make is our Q1 guidance does have the lowest margin of the year, again, in part driven by the fact that Q1 sales are typically the lightest, and because of all of the fixed costs we have in place, there is some absorption that does not occur due to the lower level of sales.
我還要補充一點:我們對第一季的指引是全年最低的利潤率,部分原因同樣是第一季銷售通常最淡;而由於我們有許多固定成本已經到位,在較低銷售水準下,會出現部分成本吸收不足的情況。
So I think those are a couple of important points. By and large, we're very pleased with the margin improvement that this plan indicates. The second half of the year was very important for us, in large part because it gave us confidence that we could give solid guidance for 2016 and that we could operate effectively on a stand-alone basis. But I do think it's important to consider the seasonality and the trending in margin when we think about 2016.
所以我認為這些是幾個重要的重點。整體而言,我們對這項計畫所顯示的毛利率改善感到非常滿意。下半年對我們非常重要,主要是因為它讓我們有信心能為2016年提供穩健的指引,並且能以獨立公司的方式有效營運。但我確實認為,在我們思考2016年時,重要的是要把季節性以及毛利率的趨勢納入考量。
- Analyst
- Analyst
Right. So maybe just year-over-year then, ex the things that are affecting margin, like cyclo, pension, and FX, what kind of year-over-year underlying margin improvement are you assuming with the 11%?
了解。那麼如果以年對年來看,扣除影響毛利率的因素,例如cyclo、退休金與外匯,對於11%這個數字,你們假設的年對年基礎毛利率改善大概是多少?
- CFO
- CFO
Yes. So essentially, we're talking about, as I said, 200 basis points from 2015 to 2016. And let me highlight a few items for you that impact that. Cyclo is about a 80 or 90 basis point drag relative to 2015. PROTOPAM is another item, that we've discussed previously, which is approximately a 30 basis point item. Foreign exchange is about a 1.6 point on a year-over-year basis margin drag, so it's a very substantial -- relative to May, it's less, on a year-over-year basis, it's even more than that. The pension, again, is about 1 point of improvement year-over-year.
是的。基本上,如我所說,我們談的是從2015到2016年約200個基點。我再為你強調幾個影響這個變化的項目。Cyclo相較於2015年約有80到90個基點的拖累。PROTOPAM是另一個我們先前討論過的項目,約為30個基點。外匯在年對年基礎上對毛利率約有1.6個百分點的拖累,因此影響非常顯著——相較於5月的假設,拖累較小;但若以年對年來看,甚至比這個還要更大。退休金方面,年對年則約有1個百分點的改善。
But then there are a number of other critical items. And again, these are the ones that I'm happiest to point out. SG&A savings, we're talking about a 2 percentage point improvement in SG&A. R&D savings, we're talking about a 60 basis point improvement. And then operationally, because many of the initiatives that we're putting in place from a mix volume standpoint, along with some of our pricing and economic value capture initiatives, along with general business growth, yield approximately a little more than 1 percentage point of margin improvement.
但另外還有一些其他關鍵項目。同樣地,這些是我最樂於指出的部分。SG&A節省方面,我們談的是SG&A改善2個百分點。研發(R&D)節省方面,我們談的是改善60個基點。此外在營運面,因為我們正在推動的多項措施(從產品組合與銷量的角度),再加上部分定價與經濟價值擷取措施,以及整體業務成長,合計帶來約略超過1個百分點的毛利率改善。
So I walked you through a number of items there, and there's a lot of moving pieces that take us from the 9% to 11%. But as I say, there are a number of important ones that we can point to operationally that are really driving this improvement, that I think, based on the second half of this year, we have confidence in as we move forward.
所以我剛才帶你走過了多個項目,從9%到11%之間有很多變動因素。但如我所說,有一些在營運面非常重要、真正推動這項改善的因素;我認為基於今年下半年的表現,我們在往前推進時對此是有信心的。
- Analyst
- Analyst
Great. Thank you for that. And then Joe, real quickly, one of the questions we're getting a lot from investors is you're articulating a plan to drive faster growth for the Company on the top line basis. And people are, I think, very curious as to how the balance will look, what the balance will look like in terms of the need to invest in the business incrementally to drive that top line growth versus what investors are looking for in terms of operating leverage in the business, as you look forward over the next couple of years. How would you respond to that kind of question about the need to invest to get top line growth, but the desire for people to see real operating leverage progress here?
很好。謝謝你的說明。接著Joe,很快問一下,我們從投資人那裡收到很多問題:你們正在闡述一個計畫,要在營收(top line)層面推動公司更快成長。我想大家非常好奇的是,未來幾年在「為了推動營收成長而需要逐步增加投資」與「投資人希望看到營運槓桿」之間,這個平衡會是什麼樣子。對於這類問題——需要投資才能帶動營收成長,但同時大家也希望看到實質的營運槓桿進展——你會怎麼回應?
- Chairman and CEO
- Chairman and CEO
Bob, we need to look this in phases. We need to bring the leverage at the same time that we invest, meaning we need to accelerate some of our cost reductions, period. Secondly, our spending in R&D today is adequate for the portfolio as we see in the near and mid term, meaning we don't need to spend more money than we're spending today as a matter of mix. And if we need to spend more money, we need to self-fund that and make sure that it does not impact our earnings.
Bob,我們需要分階段來看。我們需要在投資的同時也把槓桿做出來,也就是說,我們必須加速部分成本削減,沒有其他選擇。第二,我們目前的研發支出,對於我們在短中期所看到的產品組合而言是足夠的,也就是說,就組合而言,我們不需要比現在花更多錢。如果我們確實需要增加支出,我們必須自籌資金,並確保不影響我們的獲利。
So this is not an investment story where we have an R&D budget that is completely under funded to deliver on innovation. We just need to do a better job in allocating capital to the right franchise, they have the chance to grow faster. So I had mentioned, for instance, IPS. We'll double down in IPS to be able to get more molecules to the marketplace. So we're working on plans like this very rapidly. But that is a reallocation of resources.
所以這不是一個「研發預算嚴重不足、無法交付創新」的投資故事。我們只是需要在資本配置上做得更好,把資源配置到有機會更快成長的正確事業/產品線上。例如我提到的IPS。我們會在IPS上加碼投入,以便把更多分子(molecules)推向市場。因此我們正非常快速地制定這類計畫。但那是資源的重新配置。
I want to make sure our investors are clear that as we work to accelerate our cost reductions to provide for improved bottom line, we will create a mix change in how we spend money to be able to invest in the right things, and concurrently look at some good acquisitions that will come in and create a momentum and change in our weighted average market growth rate.
我想確保投資人清楚:當我們努力加速成本削減、以改善損益底線的同時,我們也會改變支出組合,讓我們能投資在正確的事情上;並且同時評估一些不錯的併購案,這些併購將帶來動能,並改變我們加權平均的市場成長率。
- Analyst
- Analyst
Great. Thank you very much.
很好。非常感謝。
- Chairman and CEO
- Chairman and CEO
Thank you.
謝謝。
Operator
Operator
Our next question comes from Matt Miksic with UBS.
下一個問題來自UBS的Matt Miksic。
- Analyst
- Analyst
Hello. Thanks for taking our questions. So one clarifying question, Jay, on Q1 guidance. You mentioned the puts and takes, and I think some seasonal effects that maybe show for a little -- the weakest quarter of the year, in terms of margins, and a touch below where we were expecting. Was there anything else, other than just absorption, or was there any FX impact there that you could quantify?
你好。謝謝讓我們提問。我有一個釐清問題,Jay,關於第一季(Q1)的指引。你提到一些正負因素(puts and takes),以及我想一些季節性影響,可能使得第一季——就毛利率而言——是一年中最弱的一季,並且比我們原先預期略低一些。除了產能吸收(absorption)之外,還有其他因素嗎?或是是否有外匯(FX)影響,你可以量化一下?
- CFO
- CFO
Yes, sure. Just a couple of comments in terms of Q1. Historically for Baxter, Q1 has been the weakest quarter of the year, with approximately 23% to 24% of full-year sales occurring in the quarter. And 2016 is no different for us. The result of that, of course, is you have a lower drop through, both in terms of margin and then ultimately in terms of EPS.
是的,當然。就第一季而言,我補充幾點。歷史上對Baxter來說,第一季通常是一年中最弱的一季,約占全年銷售額的23%到24%。2016年對我們也不例外。其結果當然是,無論在毛利率層面,最終到每股盈餘(EPS)層面,利潤的落差/穿透(drop through)都會較低。
And then, there is another factor, which is we do have a slightly larger FX impact in the first quarter than we do in later quarters in the year. So roughly 40% of the FX impact on a full-year basis occurs in the first quarter of the year. So really, those would be the two items that I would point to. There's nothing specific beyond that, as we look at sales and performance in 2016.
另外還有一個因素:我們在第一季受到的外匯影響會比年內後續季度稍大一些。大約全年外匯影響的40%會發生在第一季。所以我真正要指出的就是這兩點。就我們看2016年的銷售與表現而言,除此之外沒有其他特定因素。
- Analyst
- Analyst
That's great. Thank you. And then one follow-up on one of the things that's driving much of your growth in the current portfolio businesses is around pumps, and really impressive number in Q4. Stepping back and thinking about that business, as we all know, it has had its challenges in the past as a category. And I just look to get an update on how you feel you're positioned with the new business coming in from SIGMA, with some of the new FDA actions and guidelines on cyber security, and some of the competitors that have had problems with that new category of requirement, how you're positioned going forward to help mitigate the risks of other kinds of problems that you've had in the past as a group in pumps, not just Baxter, obviously.
很好。謝謝。接著追問一題:目前你們現有產品組合業務中,推動成長的很大一部分來自幫浦(pumps),而第四季(Q4)的數字非常亮眼。退一步看這個業務,如我們都知道,這個品類過去曾面臨一些挑戰。我想請你更新一下:隨著SIGMA帶來的新業務加入、FDA近期在資安(cyber security)方面的新動作與指引,以及一些競爭對手在這類新要求上遇到的問題,你們未來的定位如何,來協助降低過去在幫浦這個群組(不只是Baxter,當然)曾經遇到的其他類型問題風險?
- Chairman and CEO
- Chairman and CEO
Matt, this is Joe. I can only speak about the Baxter product. In terms of the industry, you outline well. There's always the concern. But this is not only the only programmable pump that you have in that category. You have [anthropedic] pumps. You have all kind of different things that fall into that category.
Matt,我是Joe。我只能就Baxter的產品來談。就產業而言,你描述得很到位。確實一直都會有疑慮。但在那個類別裡,不是只有這一種可程式化幫浦。你還有[anthropedic]幫浦。還有各式各樣不同的東西都歸在那個類別之下。
But speaking specifically about our business, we have launched a really good product. And you can attest to -- the testament to it is the sales growth and how we are gaining back market share and how that business is doing well. The team is executing very, very well.
但就我們的業務具體而言,我們已推出一款非常好的產品。而且你也可以證明——最好的佐證就是銷售成長、我們如何重新奪回市占率,以及該業務表現良好。團隊的執行非常、非常到位。
Our objective is to continue to improve the operation ability of the pump. We have new versions coming out in a couple more years. We have two more versions of the same platform. We are very excited about the prospect to create some new features within this pump. And we think in terms of cyber security, our pump has performed well. You can't, in this area, always guarantee 100%. We're doing the best we can to make sure the platform we have is safe and secure for the clinicians who are programming it for the patients who are receiving the fluid.
我們的目標是持續提升這款幫浦的運作能力。我們在未來幾年還會推出新版本。同一平台還會再推出兩個版本。我們對於在這款幫浦中打造一些新功能的前景感到非常興奮。而且就資安而言,我們的幫浦表現良好。在這個領域,你不可能永遠保證100%。我們會盡最大努力,確保我們的平台對為病患進行程式設定的臨床人員,以及接受輸液的病患而言,都是安全且具防護性的。
- Analyst
- Analyst
That's great. Thank you.
太好了。謝謝。
Operator
Operator
Our next question comes from Larry Keusch with Raymond James.
下一個問題來自 Raymond James 的 Larry Keusch。
- Analyst
- Analyst
Good morning, everyone. Joe, I'm wondering if we could start out perhaps just talking a little bit about how you see the health of the emerging markets as you look into 2016. And I'm not so much talking about FX rates, but just more about just the baseline fundamentals within the various regions.
各位早安。Joe,我想先請你談談你對2016年新興市場健康狀況的看法。我不是那麼想談匯率,而是更想了解各區域的基本面。
- Chairman and CEO
- Chairman and CEO
Well, as you know, read the same headlines I do read, there is a contraction in some of the major, the larger emerging market economies. Very different in nature between China and Brazil and Russia, but nonetheless, we do 25% of our business in those regions.
嗯,如你所知,我看的新聞標題跟你看的差不多,一些主要、較大型的新興市場經濟體正在收縮。中國、巴西與俄羅斯的情況本質上非常不同,但不管怎樣,我們有25%的業務在那些地區。
I think one particular thing about our business is that we are not a physician preferred product in those regions. And we are a hospital necessity. So we're talking about infusion. We're talking about dialysis. And those products are needed. So we have seen price pressure in those markets. But we probably saw that ahead of many people, because the nature of the products. So we feel that the risk of those markets for Baxter deteriorating further is pretty low.
我認為我們業務的一個特點是,在那些地區我們不是醫師偏好型產品。我們是醫院的必需品。我們談的是輸液。我們談的是透析。而那些產品是必須的。因此我們確實在那些市場看到價格壓力。但由於產品的性質,我們可能比很多人更早就看到了這點。所以我們認為,這些市場對 Baxter 而言進一步惡化的風險相當低。
With all that said, it's our responsibility to look at our portfolio in those countries and make sure that we're selling the right products to the right markets. And we're going through that process as we speak. But in terms of the headlines for Baxter is, those are necessity products in hospital settings and we've seen most of the contraction already, not saying that we're going to have them in the future, but we are not a physician preferred product company in those markets. So I feel very comfortable that our strategy at the moment is solid. But going forward, rest assured we're going to look at every region and every country to make sure that the business we have are profitable and have good prospects going forward.
話雖如此,我們有責任檢視我們在那些國家的產品組合,並確保我們把正確的產品賣到正確的市場。我們正在進行這個流程。但就 Baxter 的新聞標題而言,那些是在醫院場景中的必需品,我們已經看到大部分的收縮了——並不是說未來不會再發生——但我們在那些市場不是醫師偏好型產品公司。因此我對目前的策略非常有信心,認為它很穩健。但往後請放心,我們會檢視每個區域、每個國家,確保我們的業務具備獲利性,並且未來前景良好。
- Analyst
- Analyst
Okay. Terrific. And then I wanted to, Joe, perhaps get at, again, the growth question a little bit differently. And I think in your prepared comments, you talked about reigniting the innovation engine at Baxter, and so you talked about reallocating resources to drive inorganic and you've talked about potential -- excuse me, organic means -- and then potential organic opportunities. But as you've been there -- and I know it's a short time -- what do you really need to do to change, again, the ability of Baxter to innovate? Do you need to change the culture? Do you need to hire folks into these various categories to really drive the innovation? What needs to happen to get that engine ignited?
好的。太棒了。接著我想用另一個角度再問一次成長的問題。我想在你準備好的發言中,你提到要重新點燃 Baxter 的創新引擎,因此你談到重新配置資源以推動非有機——抱歉,是有機成長——以及潛在的有機機會。但你到任後——我知道時間不長——你認為要真正改變 Baxter 的創新能力,需要做些什麼?需要改變文化嗎?需要在這些不同領域招募人才來真正推動創新嗎?要讓那個引擎點燃,需要發生什麼事?
- Chairman and CEO
- Chairman and CEO
So just to comment on how new I am, I can tell you I know where the cafeteria is, because I eat there almost every day. So the culture of the Company is one of innovation for many years. I think by not having Baxalta's part of Baxter today really puts the spotlight how we take those franchise that have been trusted in a long-term franchises around the globe and make them more innovative, create adjacencies within our own capabilities, our four walls here for organic growth.
先評論一下我有多新:我可以告訴你我知道餐廳在哪裡,因為我幾乎每天都在那裡吃飯。所以公司的文化多年來一直是創新。我認為,今天 Baxter 不再包含 Baxalta 的部分,確實讓焦點更集中在:我們如何把那些在全球長期被信賴的事業群(franchise),做得更具創新性,在我們自身能力、我們這四面牆之內創造相鄰領域(adjacencies),以實現有機成長。
And the culture that I'm passing on to our employees is, very clearly is about having a strategic direction. And that's about 10% of the conversation. 90% of the conversation is execution. So it's making sure that once we make the allocation of capital to the right programs, that our people deliver on time or better than that. And that's all about execution.
而我傳達給員工的文化非常清楚:要有策略方向。那大約只占對話的10%。90%的對話是執行。也就是確保一旦我們把資本配置到正確的專案上,我們的人能按時交付,甚至更早。而這一切都關乎執行。
So that's what I'm watching very closely, because I think we have very, very smart people at Baxter. I'm not surprised, but I'm very pleased with what I've found here. And I want the folks of Baxter to understand that from this point when we get this strategy going, it's all about execution. And I think I have everybody behind me when it comes to that.
所以我正在非常密切地觀察這點,因為我認為 Baxter 有非常、非常聰明的人才。我並不意外,但我對我在這裡看到的一切感到非常滿意。我希望 Baxter 的同仁理解,從我們把這個策略推動起來的那一刻起,一切都關乎執行。而在這方面,我想大家都會支持我。
- Analyst
- Analyst
Okay. Terrific. Thanks very much for the comments.
好的。太棒了。非常感謝你的評論。
- Chairman and CEO
- Chairman and CEO
Thank you.
謝謝。
Operator
Operator
Our next question comes from Joanne Wuensch with BMO Capital Markets.
下一個問題來自 BMO Capital Markets 的 Joanne Wuensch。
- Analyst
- Analyst
Good morning, and nice quarter. And it's good to hear your voice on a conference call again, Joe.
早安,本季表現不錯。而且很高興再次在電話會議上聽到你的聲音,Joe。
- Chairman and CEO
- Chairman and CEO
Thank you.
謝謝。
- Analyst
- Analyst
A couple of things. First of all, we haven't heard in a while where you are on home hemodialysis, and if you can give us an update on that, that would be great. And then in no particular order, second question, is there a way to quantify the $600 million in pension impact on gross margins? And last but not least, M&A clearly is going to be a theme here. Big picture thoughts on adding additional legs to the stool and how you think about that. Thank you.
有幾件事。首先,我們有一段時間沒聽到你們在居家血液透析(home hemodialysis)方面的進展了,如果你能更新一下會很棒。然後不分先後,第二個問題:是否有辦法量化6億美元的退休金影響對毛利率的衝擊?最後但同樣重要的是,併購(M&A)顯然會是這裡的一個主題。從大方向來看,對於為「凳子」再加幾條腿(增加成長支柱)的想法,以及你如何思考這件事。謝謝。
- Chairman and CEO
- Chairman and CEO
Thank you. And how are you? Listen, I'm very, very excited about home hemodialysis, first of all. It is a, what I call, blue ocean for the Company. It is a great clinically needed innovation. It is not an easy market to get in, because the technology has to be absolutely perfect for bringing this therapy to the home. But we think we have the right technology, and we're working very hard to refine the technology. Right now, we already have kicked off our US clinical trial for VIVIA, and we're excited about that. In Europe, we have early patients and we're learning very quickly about our VIVIA platform. And the use of this device is proven to be well received in Europe.
謝謝。你最近如何?聽著,首先我對居家血液透析非常、非常興奮。這是我所說的公司的「藍海」。這是一項臨床上高度需要的重大創新。這不是一個容易進入的市場,因為要把這種治療帶到家中,技術必須絕對完美。但我們認為我們擁有正確的技術,而且我們正非常努力地精進這項技術。目前我們已經啟動 VIVIA 在美國的臨床試驗,我們對此感到興奮。在歐洲,我們已有早期病患,並且正非常快速地從 VIVIA 平台學習。而這個裝置在歐洲的使用已被證明獲得良好接受度。
So we like our technology. It is an area I will call is in the strategic path. And why is it strategic? Because it's high end market growth, potential for good revenue per patient, but more so, the therapy itself is absolutely fantastic for the hemodialysis patient to be able to do this at home. So we're going to continue to improve our technology, and we will try to put some momentum behind accelerating the US trial, as much as we can, and work with the agencies and CMS and see if we can get this technology at a different level.
所以我們喜歡我們的技術。這是我會稱之為在策略路徑上的一個領域。為什麼它具有策略性?因為它是高端市場成長,具備每位病患帶來良好營收的潛力;更重要的是,對血液透析病患而言,能在家中進行這項治療本身就非常出色。因此我們會持續改善我們的技術,並會盡可能推動加速美國試驗的動能,同時與主管機關及 CMS 合作,看看能否把這項技術提升到不同的層級。
- CFO
- CFO
Joanne, you asked a question about pension and quantifying, and you commented on $600 million. I think -- I hope I didn't say that -- that's an overstatement in terms of the impact on operating margin. Unplanned, it's about 60 basis points, 6-0, which is closer to $60 million of unplanned benefit.
Joanne,你問了一個關於退休金與量化的問題,並提到6億美元。我想——我希望我沒有那樣說——就對營業利益率的影響而言,那是被高估了。若以非計畫性來看,大約是60個基點,6-0,較接近約6,000萬美元的非計畫性收益。
But maybe taking a step back to talk about the overall impact of pension. Overall, we expect approximately a $0.14 benefit year-over-year from pension. $0.07, roughly of that, it relates to the retained stake contribution that we plan to make in the coming month or so.
不過也許先退一步,談談退休金的整體影響。整體而言,我們預期退休金年對年約帶來0.14美元的利益。其中約0.07美元,與我們計畫在接下來一個月左右進行的保留持股出資有關。
And then the remaining portion, there's a few different pieces. First, the actual discount rate used to measure the liability has increased and the result of that is approximately a $0.035 benefit. Second, as we've evaluated our accounting for our pension plan, we made three adjustments. One is, we updated the mortality table that we're using. The second is, we are now employing the recently approved methodology for accounting for discount rate, and that's a benefit. And then the return on asset assumption is an item that we've lowered. So those three accounting changes that we've made impact us positively by about $0.02. And then we have some amortized losses that are rolling off, so that's about $0.01.
然後剩餘的部分,包含幾個不同的項目。第一,用於衡量負債的實際折現率已上升,其結果約帶來0.035美元的利益。第二,在我們檢視退休金計畫的會計處理時,我們做了三項調整。其一是更新我們使用的死亡率表。其二是我們現在採用近期核准的折現率會計方法,這會帶來利益。另外,資產報酬率假設是我們已下調的一個項目。因此,我們所做的這三項會計變更,合計對我們的正面影響約為0.02美元。此外,還有一些攤銷損失正在到期退出,因此約為0.01美元。
So in combination, we're talking about a $0.14 year-over-year impact. And importantly this counteracts some of the negatives, like the lack of sundry income that we experienced in 2016, along with the significant headwind on foreign exchange. But overall, the pension impact is in that order of magnitude.
所以合併起來,我們談的是年對年0.14美元的影響。而且重要的是,這抵消了一些負面因素,例如我們在2016年經歷的雜項收入缺口,以及外匯帶來的顯著逆風。但整體而言,退休金影響大致就是這個量級。
- Analyst
- Analyst
Thanks. And my last question, add on a leg of the stool?
謝謝。那我最後一個問題,「凳子再加一條腿」?
- Chairman and CEO
- Chairman and CEO
We will continue to work on inorganic and organic areas. I would say to you that a leg of the stool may be just enhancing a franchise that we have. We spoke about IPS and very, very excited about that. I like our Specialty Injectable business today, and I think augmenting that can become a real good business. And in terms of white space, it's little early. We need to get our capital allocation going well; and once we have that well segmented within our population and our management objectives, then we can do a white space analysis and we'll proceed on going down that path. But we really have enough opportunities right now to augment the current businesses, and they are adjacencies, as well. Thank you.
我們會持續在外延式與內生成長領域努力。我會說,「凳子的一條腿」可能就是強化我們既有的一個特許經營。我們談到IPS,對此非常、非常興奮。我喜歡我們目前的專科注射劑業務,我認為擴充它可以成為一門非常好的生意。至於白地機會,現在談還有點早。我們需要把資本配置運作好;一旦在我們的客群與管理目標中把它清楚分段,接著就能做白地分析,並沿著那條路徑推進。但我們目前確實已有足夠的機會來擴充現有業務,而且也屬於相鄰領域。謝謝。
- Analyst
- Analyst
Thank you.
謝謝。
Operator
Operator
Our final question comes from Glenn Novarro with RBC Capital Markets.
我們最後一個問題來自RBC Capital Markets的Glenn Novarro。
- Analyst
- Analyst
Hello. Good morning, guys. Two questions. One, in the fourth quarter, your Surgical business was in the low single digits, and you said it grew in line with the market. And then for 2016, you're talking about the Surgical business growing 3% to 4%. So are you saying that you expect surgical volumes and utilization to pick up in 2016, or are you just saying the better rates are more specific to Baxter? So any thoughts on utilization rates, especially the US.
你好。各位早安。兩個問題。第一,第四季你們的外科業務是低個位數成長,你們說成長與市場一致。而對2016年,你們談到外科業務成長3%到4%。所以你們是說你們預期2016年外科手術量與使用率會回升,還是只是說較好的價格更偏向是Baxter自身的因素?所以對使用率,特別是美國,有什麼看法?
And then my second question had to do with the US Renal business, specifically with PD. I know PD did better in the fourth quarter. That was some of your new products. But are you also seeing an increase in penetration in the US with PD? Thanks.
第二個問題是關於美國腎臟業務,特別是PD。我知道PD在第四季表現較好。那是你們一些新產品帶動的。但你們是否也看到PD在美國的滲透率提升?謝謝。
- Chairman and CEO
- Chairman and CEO
Glenn, how are you?
Glenn,你好嗎?
- Analyst
- Analyst
Good.
很好。
- Chairman and CEO
- Chairman and CEO
So listen, the utilization that we see -- I just want to clarify, the next year's growth is 2% to 3%.
所以聽著,我們看到的使用率——我想先澄清一下,明年的成長是2%到3%。
- VP of IR
- VP of IR
For surgical care.
就外科照護而言。
- Chairman and CEO
- Chairman and CEO
For surgical care. So the utilization remains at a good point in the US. I would say the US has shown really good resilience, and we're happy about that.
就外科照護而言。所以在美國,使用率仍維持在不錯的水準。我會說美國展現了非常好的韌性,我們對此很高興。
There's a couple things about the Surgical business, one that our anesthesia gasses are performing very well, and we need to do a better job in our biosurgery business. We're going to be coming up with some specific actions in terms of execution, but also how we're going to manage that business on a global basis, as well as that is an area that we probably should be looking to augment our portfolio. It's a great area of opportunity. Baxter has fantastic franchises within that category, and we want to make sure we don't miss the opportunity to take advantage of the market growth.
外科業務有幾件事:其一,我們的麻醉氣體表現非常好;而在我們的生物外科業務方面,我們需要做得更好。我們將提出一些具體的執行行動,也包括我們將如何在全球範圍內管理該業務;同時,這也是我們可能應該考慮擴充產品組合的領域。這是一個很棒的機會領域。Baxter在該類別中擁有非常出色的特許經營,我們希望確保不會錯失把握市場成長的機會。
So speaking about the PD business, we are growing our patient basis. So that is market share growth. And I'm going to tell you, our new technology, new platform, AMIA, is fantastic, and we're having some really early successes and we're looking for a very good 2016 in that arena.
至於PD業務,我們正在擴大病患基礎。因此那是市占率的成長。我可以告訴你,我們的新技術、新平台AMIA非常出色,我們已取得一些非常早期的成功,並期待在2016年於該領域有非常好的表現。
- Analyst
- Analyst
Okay. Great. Welcome back, Joe.
好的。很好。歡迎回來,Joe。
- Chairman and CEO
- Chairman and CEO
Thank you, Glenn.
謝謝你,Glenn。
- VP of IR
- VP of IR
Thank you. Yes, Stephanie, we'll conclude the call.
謝謝。是的,Stephanie,我們將結束本次電話會議。
Operator
Operator
Thank you. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you all for participating. You may now disconnect.
謝謝。各位女士、先生,Baxter International今天的電話會議到此結束。感謝各位參與。您現在可以掛線。